BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Treatment of Vasomotor Symptoms in Korean Post Menopausal Women
Phase 3
Completed
- Conditions
- Vasomotor Symptoms
- Interventions
- Drug: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)Drug: Placebo
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 90
- Registration Number
- NCT00651599
Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.
Phase 3
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Drug: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)Drug: Placebo
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 534
- Registration Number
- NCT00651469
Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis
Phase 2
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: PlaceboDrug: Ciprofloxacin (Cipro Inhale, BAYQ3939)
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 288
- Registration Number
- NCT00645788
Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
Phase 1
Completed
- Conditions
- Hypertension, PulmonaryPulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 23
- Registration Number
- NCT00640315
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
Phase 3
Completed
- Conditions
- Macular Degeneration
- Interventions
- Drug: RanibizumabBiological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2014-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1240
- Registration Number
- NCT00637377
Russian Kogenate Pediatric Study
Phase 4
Completed
- Conditions
- Hemophilia A
- Interventions
- Drug: rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per weekDrug: rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg)Drug: rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT00632814
Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction
Phase 3
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: PlaceboDrug: Vardenafil ODT (STAXYN, BAY38-9456)
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 362
- Registration Number
- NCT00631969
A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles
Phase 2
Completed
- Conditions
- Contraception
- Interventions
- Drug: BAY86-4891 (Estradiol / Drospirenone)
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 103
- Registration Number
- NCT00631124
Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980
Phase 1
Completed
- Conditions
- Hemophilia A
- Interventions
- Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)Biological: Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 27
- Registration Number
- NCT00629837
Sorafenib Long Term Extension Program
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 206
- Registration Number
- NCT00625378
© Copyright 2025. All Rights Reserved by MedPath